Alpha Tau Medical Ltd. (DRTS)
Alpha Tau Medical Ltd. (DRTS) Stock Price, Analysis & Data
| Precio de compra | 10.37 |
| Capitalización de mercado | 1.32B |
| Ingresos (TTM) | n/a |
| Beneficio neto (TTM) | -92.57M |
| Beta | 1.19 |
| EPS (TTM) | -1.04 |
| Ratio PER (TTM) | n/a |
| Adelante PE | -27.11 |
| P/B (TTM) | 18.57 |
| P/S (TTM) | n/a |
| Earnings Date | Nov 19, 2026 |
| Precio de venta | 18.3 |
| Volumen | 472,472 |
| Volumen medio (20D) | 798,550 |
| Abierto | 14.40 |
| Anterior Cerrar | 14.26 |
| Rango del día | 14.17 - 14.70 |
| Rango de 52 semanas | 3.03 - 14.75 |
| analista | n/a |
| Precio objetivo | n/a |
| Dividendos | n/a |
| Fecha ex dividendo | n/a |
Acerca de DRTS
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The ...
Desempeño financiero
En 2025, los ingresos de Alpha Tau Medical fueron 0, un aumento de undefined% en comparación con 0 del año anterior. Las ganancias fueron -42.63M, un aumento de 34.26%.
Estados financierosSorpresa de resultados
Los analistas proyectan ingresos de ... Actualizar
2 semanas hace · Simply Wall St.
Alpha Tau Medical (DRTS) Is Down 5.7% After Early-Stop Success In Alpha DaRT Combo TrialIn July 2026, Alpha Tau Medical reported positive podium-presented data from a single-center trial showing that its Alpha DaRT device combined with pembrolizumab achieved a 100% objective response rat...
